In fact, trastuzumab (a HER2-neutralizing antibody) and ramucirumab (an anti-VEGFR-2 antibody) have been introduced with or without combined treatment of cytotoxic agents that have improved the survival of patients with gastric cancer; however, the overall survival of patients with advanced gastric cancer remains discouraging1. The gene discussed is ERBB2; the disease is gastric cancer.